Abstract
Previous studies have shown that treatment with daily injections of human parathyroid peptide (hPTH) 1-34 increase axial cancellous bone mass partially at the expense of peripheral cortical bone. In the present work the same hPTH 1-34 regime given for 12 months has been combined with oestrogen or nandrolone therapy to control peripheral bone resorption. Spinal and iliac cancellous (but not cortical) bone increased by 40%–50% above initial values while no perceptible changes occurred in radial cortical or cancellous bone. The evidence of radiokinetic and histomorphometric studies performed before and in the last months of treatment suggested that bone remodeling had proceeded through a transient anabolic phase with increased activation, but that activation had become normal after 11–12 months in the cancellous bone of the ilium whereas it continued to be raised elsewhere in the skeleton. It is concluded that in combination with oestrogens, hPTH peptides given daily injections hold great promise for the treatment of patients with osteoporosis who have already lost substantial amounts of spinal cancellous bone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Briançon D, Meunier PJ. Treatment of osteoporosis with fluoride, calcium and vitamin D. Orthop Clin North Am 1981;12:629–48.
Reeve J, Meunier PJ, Parsons JA, et al. The anabolic effect of human parathyroid hormone fragment (hPTH 1-34) therapy on trabecular bone in involutional osteoporosis: report of a multi-centre trial. BMJ 1980;280:1340–4.
Rasmussen H, Bordier P, Marie P, et al. Effect of combined therapy with phosphate and calcitonin on bone volume in osteoporosis. Metab Bone Dis Rel 1980;2:107–11.
Meunier PJ, Bordier P, Marie P, et al. Effect of combined therapy with phosphate and calcitonin on bone volume in osteoporosis with drugs that increase bone formation: sodium fluoride, hPTH 1-34, ADFR concept. In: Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peck WA, Riggs BL, editors. Osteoporosis, vol 2. Åalborg: Stiftsbogtrykkeri, 1984:595–602.
Marie PJ, Caulin F. Mechanisms underlying the effect of phosphate and calcitonin on bone histology in postmenopausal osteoporosis. Bone 1986;7:17–22.
Bradbeer JN, Arlot M, Reeve J, Meunier PJ. Human parathyroid peptide (hPTH 1-34) treatment increases the mean wall thickness of iliac trabecular packets of new bone in patients with crush fractures osteoporosis. J Bone Miner Res 1988;3:S160.
Hesp R, Hulme P, Williams D, Reeve J. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1-34). Metab Bone Dis Rel 1981;2:331–4.
Nordin BEC, Horsman A, Crilly RG, Marshall DH, Simpson M. Treatment of spinal osteoporosis in postmenopausal women. BMJ 1980;1:451–4.
Geusens P, Dequeker J. Long-term effect of nandrolone decanoate, la-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner 1986;1:347–57.
Reeve J, Arlot M, Price TR, et al. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis. Eur J Clin Invest 1987;17:421–8.
Genant HK, Cann CE, Pozzi-Mucelli RS, Kanter AS. Vertebral mineral determination by quantitative CT: clinical feasibility and normative data. J Comput Assist Tomogr 1983;7:554.
Ruegsegger P, Elsasser U, Anliker M, Guehm H, Kind H, Prader A. Quantitation of bone mineralization using computed tomography. Radiology 1976;121:93–7.
Reeve J, Green JR, Hesp R, Hulme P. Rates of new bone formation in patients with crush fracture osteoporosis. Clin Sci 1982;63:153–60.
Wootton R, Reeve J. The relative merits of various techniques for measuring radiocalcium absorption. Clin Sci 1980;58:287–93.
Reeve J, Arlot ME, Chavassieux PM, et al. The assessment of bone formation and bone resorption in osteoporosis: a comparison between tetracycline-based iliac histomorphometry and whole body85Sr kinetics. J Bone Miner Res 1987;2:479–89.
Reeve J, Wootton R, Hesp R. A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as tracer for bone calcium. Calcif Tissue Int 1976;20:121–35.
Burkinshaw L, Marshall DH, Oxby CB, Spiers FW, Nordin BEC, Young MM. Bone turnover model based on a continuously expanding exchangeable calcium pool. Nature 1969;222:146–8.
Meunisr PJ, Courpron P, Edouard C, et al. Bone histomorphometry in osteoporotic states. In: Barzel US, editor. Osteoporosis II. New York: Grune and Stratton. 1979:27–47.
Arlot ME, Edouard C, Meunier PJ, Neer RM, Reeve J. Impaired osteoblast function is osteoporosis. Comparison between calcium balance and dynamic histomorphometry. BMJ 1984;289:517–20.
Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Miner Res 1987;2:595–610.
Slovik DM, Rosenthal DI, Doppelt SH, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986;1:377–81.
Hesch R-D, Busch U, Prokop M, Delling G, Rittinghaus E-F. Increase of vertebral density by combination therapy with pulsatile 1-38 hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989;44:176–80.
Reeve J, Davies UM, Hesp R, McNally E, Katz D. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. BMJ 1990;301:314–18,477.
Reeve J, Bradbeer JN, Arlot M, et al. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporosis Int 1991;1:162–70.
Neer RM, Slovik D, Doppelt S, et al. The use of parathyroid hormone plus 1,25-dihydroxyvitamin D to increase trabecular bone is osteoporotic men and postmenopausal women. In; Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis 1989. Copenhagen: Osteopress ApS, 1987:829–35.
Rittinghaus EF, Busch U, Prokop M, Delling O, Hesch RD. Increase of vertebral density in osteoporotic patients: combination therapy with 1-38 hPTH and cyclic addition of calcitonin nasal spray. In: Christiansen C, Johansen JS, Riis BJ, editor. Osteoporosis 1987. Copenhagen: Osteopress ApS, 1987:888–91.
Vogel M, Hesch RD, Delling G. Morphologische Untersuchung der Beckenkammspongiosa bei Patienten mit Osteoporose unter einer Kombinationstherapie mit pulsatiler Gabe von Parathormon (1-38 hPTH) und sequentialler Verabreichung von Calcitonin-Nasenspray. Med Klin 1990;85:82–6.
Civitelli R, Agnusdei D, Nardi P, Zacchei F, Avioli LV, Gennari C. Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D 1α-hydroxylase reserve in postmenopausal osteoporosis. Calcif Tissue Int 1988;42:77–86.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reeve, J., Arlot, M.E., Bradbeer, J.N. et al. Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporosis Int 3 (Suppl 1), 199–203 (1993). https://doi.org/10.1007/BF01621906
Issue Date:
DOI: https://doi.org/10.1007/BF01621906